Want to see INBP full AI Analyst Report?
INBP Stock Chart & Stats
$0.16
<$0.01(6.38%)
At close: 4:00 PM EDT
$0.16
<$0.01(6.38%)
Day’s Range― - ―
52-Week Range$0.14 - $0.42
Previous CloseN/A
Volume7.89K
Average Volume (3M)13.95K
Market Cap
$5.53M
Enterprise Value$4.19M
Total Cash (Recent Filing)$4.47M
Total Debt (Recent Filing)$3.08M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding31,059,610
10 Day Avg. Volume2,267
30 Day Avg. Volume13,953
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.32
Price to Sales (P/S)0.13
P/FCF Ratio6.25
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit5.24
Enterprise Value/Ebitda-3.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageManageable leverage gives INBP financial flexibility to support operations and address disruption without the balance-sheet pressure associated with heavy borrowing. Although debt rose in 2026 as equity declined, the capital structure remains a relative stabilizer.
Positive Cash GenerationOperating cash flow and free cash flow stayed positive in every year provided, including 2026 despite the net loss. This cash-generation record offers an internal funding cushion and is a durable offset to weak accounting profitability, even as the latest decline warrants caution.
Experienced Operations LeadershipA seasoned operations leader with more than 35 years across pharmaceutical, nutraceutical, supplement and contract manufacturing joined MDC. His remit over execution, quality, productivity and scalable growth could strengthen the operating platform over coming quarters.
Bears Say
Revenue And Earnings CollapseRevenue falling to zero alongside a sizeable net loss signals a severe disruption in the core operating model and sharply reduces earnings visibility. Unless operations recover, the collapse can weaken customer confidence, constrain reinvestment and undermine the company’s ability to generate sustainable profits.
Sharp Free Cash Flow DeclineThe sharp 2026 decline in free cash flow weakens the financial cushion available to fund operations, improve facilities or absorb further volatility. Positive cash generation remains helpful, but the recent deterioration raises questions about how durable internal funding will be if weak performance persists.
Profitability VolatilityLong-term margin compression and swings from strong returns on equity to weak or negative results indicate unstable capital efficiency. This volatility makes the earnings base less dependable, limits confidence in recurring profitability and increases the challenge of restoring durable shareholder returns.
Integrated BioPharma News
INBP FAQ
What was Integrated BioPharma Inc’s price range in the past 12 months?
Integrated BioPharma Inc lowest stock price was $0.14 and its highest was $0.42 in the past 12 months.
What is Integrated BioPharma Inc’s market cap?
Integrated BioPharma Inc’s market cap is $5.53M.
When is Integrated BioPharma Inc’s upcoming earnings report date?
Integrated BioPharma Inc’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Integrated BioPharma Inc’s earnings last quarter?
Integrated BioPharma Inc released its earnings results on Sep 25, 2026. The company reported -$0.044 earnings per share for the quarter.
Is Integrated BioPharma Inc overvalued?
According to Wall Street analysts Integrated BioPharma Inc’s price is currently Overvalued.
Does Integrated BioPharma Inc pay dividends?
Integrated BioPharma Inc does not currently pay dividends.
What is Integrated BioPharma Inc’s EPS estimate?
Integrated BioPharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated BioPharma Inc have?
Integrated BioPharma Inc has 31,059,610 shares outstanding.
What happened to Integrated BioPharma Inc’s price movement after its last earnings report?
Integrated BioPharma Inc reported an EPS of -$0.044 in its last earnings report. Following the earnings report the stock price went down -7.104%.
Which hedge fund is a major shareholder of Integrated BioPharma Inc?
Currently, no hedge funds are holding shares in INBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrated BioPharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.